Customers of Atlas Biomed are angry and worried about what's happened to the highly sensitive data they shared.

Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in ...

Personal data of nearly half of the popular genetic testing company's customers -- 6.9 million people -- was exposed in the data breach.

Adjusted EPS was $0.31, significantly above the expected loss. The company is encouraged by preliminary results in testing ...

These findings demonstrate disparities in precise genetic diagnosis are not due to diagnostic yields ... GeneDx is at the ...

(“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are ... it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic ...

Meridell Achievement Center specializes in behavioral programs for adolescents. Dr. Barbara Matthews, Licensed Psychologist, ...

HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...

Analyst Puneet Souda from Leerink Partners maintained a Buy rating on NeoGenomics (NEO – Research Report) and keeping the price target at ...

BURLINGTON - Azenta, Inc., a life science company at 200 Summit Dr. in Burlington, recently announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta ...